EspaƱol
Questions About Cancer? 1-800-4-CANCER
  • Email

Clinical Trials Search Results

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
  •          
Help with display options.
Results 1-23 of 23 for your search:
Drug:  nivolumab
Find trials that include:  Any drugs shown
Trial Status:  Closed
Start Over
        Show
1.

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA209-017, 2011-004792-36, NCT01642004

2.

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA209-025, 2011-005132-26, NCT01668784

3.

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA209-057, 2012-002472-14, NCT01673867

4.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA209-037, 2012-001828-35, NCT01721746

5.

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA209-066, 2012-003718-16, NCT01721772

6.

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA209-067, 2012-005371-13, NCT01844505

7.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Temporarily closed
Age: 12 months to 30 years
Sponsor: NCI
Protocol IDs: NCI-2014-01222, ADVL1412, UM1CA097452, NCT02304458

8.

Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA209-010, NCT01354431

9.

Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA209-063, 2012-003965-16, NCT01721759

10.

Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA209-064, NCT01783938

11.

Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA209-069, 2013-002018-11, NCT01927419

12.

Phase: Phase II
Type: Treatment
Status: Closed
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ONO-4538-09, NCT02175017

13.

Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA209-001 ST, MDX1106-01, NCT00441337

14.

Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA209-003, MDX1106-03, NCT00730639

15.

Phase: Phase I
Type: Treatment
Status: Closed
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ONO-4538-01, NCT00836888

16.

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA209-004, (MDX1106-04), NCT01024231

17.

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 16 and over
Sponsor: NCI, Other
Protocol IDs: MCC-15400, NCI-P-7997, CA209-006/007, 10-15526-99-01, 7997, NCT01176461

18.

Phase: Phase I
Type: Behavioral study, Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA209-009, 2011-005379-18, NCT01358721

19.

Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA209-016, NCT01472081

20.

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: Over 18
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA209-038, 2012-001840-23, NCT01621490

21.

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA220-008, NCT01629758

22.

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ONO-4538-13, NCT02261285

23.

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ONO-4538-14, NCT02261298
New Search